Clinical Trial
The AML17 Clinical Trial is now open!
(Currently open for non-APL only)
Registered Trial Centre staff can now log in to the Online Trial system. This Clinical Trial software is a unique secure interface for patient data entry and drug randomisation.
Trial Software - Training Version
Trial staff can now log in to the AML-17 Online Trial Training Version
What are the drugs being tested?
Excerpt from Patient Information Sheet 1:
For most patients with AML, the standard treatment involves
various combinations of three drugs called Daunorubicin, Cytosine
Arabinoside (ara-C for short) and Etoposide. The two best
treatments are daunorubicin and ara-C (DA for short) or these two
drugs with etoposide added (ADE for short). All of these drugs
will damage your immune system and make your hair fall out.
Most people will get a very sore mouth called mucositis and you will
have treatment for this. If you don’t have the special
leukaemia called APL, you would receive either ADE or DA
chemotherapy if you decide not to go into this trial.
At this stage, we are testing the benefit of adding a more targeted
chemotherapy called Mylotarg to these treatments. This is a
special chemotherapy that is attached to a targeting protein called
an antibody. This antibody recognises the leukaemia cells and
delivers the chemotherapy straight to those cells. We think
this might increase the number of leukaemia cells we can kill
without increase the side-effects because Mylotarg is targeted.
About 4 out 5 people in the trial will get Mylotarg in the first
course. Its main side effects are that it can cause patients
to get a little shivery when it is going into their veins and it
sometimes upsets a blood test called liver enzymes. We will
generally notice that before there is any problem. Very rarely
it can cause more serious liver upset that might need extra
treatment.
Quick Links
Clinical Trial Login (Training Version)
Website and Clinical Trial Online Software is created by Click & Fix